Table 2.
Number of Subjects in Each Randomization Group Experiencing Adverse Effects
No. of Subjects |
||
---|---|---|
Teriparatide (n = 10) | Placebo (n = 11) | |
Lightheadedness | 4 | 6 |
Muscle pain or spasm | 3 | 4 |
Nausea | 1 | 5 |
Vomiting | 1 | 3 |
Headache | 6 | 5 |
Injection site ecchymoses, bruising, erythema | 6 | 9 |
Serum Ca above normal range | 2 | 0 |
24-h urine calcium >400 mg | 3 | 1 |